Replimune Group, Inc. (REPL) stock
REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 6, 2026Score 1/30
$21.78−1.50 (-6.44%)
Close on Nov 11, 2026Market cap $2.06BP/E –Yield –
Replimune price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Replimune's price to book ratio was 17.3× on Nov 11, 2026, against 3.0× a year earlier. Over the last 5 years it ranged from 0.9× to 17.3×, with a median of 2.0×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 17.3× | +14.4 |
| 2025 | Dec 31, 2025 | 2.9× | +0.7 |
| 2024 | Dec 31, 2024 | 2.2× | +1.1 |
| 2023 | Dec 29, 2023 | 1.1× | −2.5 |
| 2022 | Dec 30, 2022 | 3.5× | +0.7 |
| 2021 | Dec 31, 2021 | 2.8× | −3.1 |
| 2020 | Dec 31, 2020 | 5.9× | +2.1 |
| 2019 | Dec 31, 2019 | 3.8× | +1.7 |
| 2018 | Dec 31, 2018 | 2.1× | – |
See a number that looks wrong?